BioSpace News Archive

Arecor Limited announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.

Growth capital to support expansion of Suvoda’s clinical trial software and services

Applied DNA Sciences, Inc., announced it plans to release financial results for its fiscal 2019 fourth quarter ended September 30, 2019 after market close on Thursday, December 12, 2019.

Vedanta Biosciences eligible for an additional $3.5 million upon completion of certain milestones

So-Young International Inc., the most popular online destination for discovering, evaluating and reserving medical aesthetic services in China, announced the appointment of Dr. Haipeng Zhang, also known as Feng Tang, to its board of directors.

Osivax announced that it has entered into an agreement with the United States’ National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to further advance the development of its lead universal flu vaccine candidate, OVX836.

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that NP-120, its repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis, showed dramatic superiority over Gefapixant, Merck’s lead phase 3 trial drug, in a well accepted acute cough in-vivo animal study.

ChromaDex and Matakana Health commit to continued sales growth in Oceania, following approval from Australian regulatory body

Pivot Pharmaceuticals Inc.announced its corporate name change to BetterLife Pharma Inc.

Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019